Physician profile
Shasta Patrick
NPI 1386414225
$475.09
in general payments reported to CMS, 2019-2025
14 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $188 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $188.32 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $66.34 | 2025 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $38.30 | 2024 | Rexulti |
| Pfizer INC. | $19.65 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.60 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $18.56 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $18.22 | 2024 | Airsupra |
| Lilly USA, LLC | $17.96 | 2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.23 | 2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.90 | 2024 | Xifaxan |
| Amgen INC. | $14.83 | 2024 | Otezla, Repatha |
| Abbvie INC. | $14.33 | 2024 | |
| Tactile Systems Technology INC | $14.31 | 2025 | Flexitouch Plus, Nimbl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.54 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shasta Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.